Department Metrics

• 2/2 Ponce Health Sciences University-Moffitt Cancer Center Partnership
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,PI (MPI):Monteiro, A.,Project PI:Peres, L.
• Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Heterogeneity of metastatic small cell lung cancer; implications for the design of effective immunotherapies
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Beg, A.,PI (MPI):Haura, E.
• Tissue-Anchored vs. Circulating Constructs for Immunometabolic Resolution of Psoriasis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Targeting dendritic cells to improve cancer immunotherapy
  Award Number:
  Sponsor: Cancer Research Institute
  PI:Ruffell, B.
• Defining Impact of in SITU Activation of CD40 and Type 1 Interferon Signaling on theTME and Systemic T Cell Immunity in Murine models and cancer patients
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Beg, A.
• Impact and Utilization of Scalable Functional Assays in Alagille Syndrome
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Luca, V.
• Moffitt ACS Post-Baccalaureate Diversity in Cancer Research (MAP-DICR)
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• ENCOURAGE Diversity
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• Cancer screening behaviors among people with and without HIV in All of Us
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,Project PI:Islam, J.

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib with or without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); Imlunestrant (); LY2835219 (Abemaciclib); Radiotherapy ()

CLINICAL TRIAL 21341
A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Ziv-aflibercept ()

CLINICAL TRIAL 21448
Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
Condition: Breast
Intervention:

CLINICAL TRIAL 21676
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases (TARGET-TNBC)
Condition: Breast
Intervention: Sacituzumab Govitecan (); Zimberelimab ()

CLINICAL TRIAL 21757
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
Condition: Breast
Intervention: Radiotherapy ()

CLINICAL TRIAL 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()

CLINICAL TRIAL 22367
The Impact Of Inflammation On HSPC Composition And Disease Progression In Chronic Myelomonocytic Leukemia (CMML INTERCEPT STUDY) SUB-TITLE: Intercepting CMML Disease Progression Driven by Acute Inflammation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22574
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Relatlimab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 23184
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy (CARIsMA)
Condition: Malignant Hematology
Intervention: Placebo ()

CLINICAL TRIAL 23240
A Phase 1, Open Label Single-Arm Two-Part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy Of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subjects with Solid Tumors Harboring Genetic Alterations in the MAPK Pathway And With Other Solid Tumors
Condition: Cutaneous
Intervention: NST-628 ()

CLINICAL TRIAL 23433
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer following Neoadjuvant Chemotherapy and Surgery
Condition: Breast
Intervention:

CLINICAL TRIAL 23548
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients with Advanced Hematologic Malignancies
Condition: Malignant Hematology
Intervention: STX-0712 ()

CLINICAL TRIAL 23598
A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Condition: Genitourinary
Intervention: Sacituzumab tirumotecan ()

CLINICAL TRIAL 23706
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (Yescarta)

CLINICAL TRIAL 23821
Development of a peripheral blood assay to replace BM evaluation in cytopenia - a multi-Center observational study
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 23901
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052667 as a Single Agent and in Combination Therapy in Participants 18 Years of age and Older with Bladder Cancer
Condition: Genitourinary
Intervention: BCG (); PF-02921367 (); PF-06801591 (Sasanlimab); PF-08052667 (); Sasanlimab ()

CLINICAL TRIAL 24030
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
Condition: Breast
Intervention:

CLINICAL TRIAL 24179
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy ENAiBLE
Condition: Genitourinary
Intervention:

• Sobierajska E, Medina CB. The cost of persistence: MEK and metabolic demand. Immunity. 2026 Aug.59(8):2058-2060. Pubmedid: 42580317.
• Silvane L, Zelenka T, Talada DP, Cismasiu VB, Islam S, Singh RP, Ngove Z, Chakraborty S, Hall MS, Blauvelt JL, Eksioglu E, Manrique SZ, Johnson JO, Obermayer AN, Alfaro A, Huang W, Sarnaik A, Tarhini AA, Mullinax JE, George E, Hwu P, Davila E, Conejo-Garcia JR, Bryceson YT, Chen DT, Shaw TI, Pilon-Thomas S, Avram D. BCL11B targeting in tumor CD8 + T cells amplifies anti-tumor response by blocking exhaustion while promoting stemness and cytotoxicity. bioRxiv. 2026 Aug. Pubmedid: 42601873. Pmcid: PMC13470569.
• Martinez-Planes E, Ramello MC, Fontela MG, Shokri MR, Tran T, Darville L, Koomen J, Kim Y, Abate-Daga D. C-terminal CD28 phosphorylation, pY218, modulates IL-2 secretion and therapeutic effect of CAR-T cells. Mol Ther. 2026 Aug. Pubmedid: 42642932.
• Le THN, Nguyen QT, Kim Y, Balkaran V, Bhathivi T, Pilon-Thomas S, Markowitz J. pAc/Emm55 increases anti-melanoma immunity via TLR2 signaling in dendritic cells and improves checkpoint blockade efficacy. Front Immunol. 2026 Aug.17:1863894. Pubmedid: 42688222. Pmcid: PMC13534055.
• Lindenbergh PL, Rajasekhar VK, Linkov I, Mansilla-Soto J, Hanina SA, Sadelain M. Control of breast cancer patient-derived xenografts by CD70-targeted HIT-CAR T cells. Front Immunol. 2026 Aug.17:1852493. Pubmedid: 42718816. Pmcid: PMC13553483.
• Mandal G, Biswas S, Anadon CM, Tamuli B, Chaurio RA, Lopez-Bailon LU, Plappert N, Carrion-Estrada D, Mine JA, Lai CH, Moreno AP, Johnson J, Moran-Segura CM, Fang B, Marchion D, Chaudhary N, Terry KL, Sasamoto N, Townsend MK, O'Brien J, Antonia SJ, Tworoger SS, Yu X, Rodriguez PC, Conejo-Garcia JR. Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression. iScience. 2026 Aug.29(8):116757. Pubmedid: 42472098. Pmcid: PMC13380442.
• Karapetyan L, Xu J, Ward K, Kalos D, Schachner B, Ali J, Song X, Kuriakose J, Hall MS, Chau J, Cox CA, Al-Bzour AN, Falahat R, Perez MC, Mullinax JE, Zager JS, Gonzalez R, Sondak VK, Tsai KY, Messina JL, Moran-Segura C, Lopez-Blanco N, Alleyne AE, Nguyen JV, Schell MJ, Markowitz J, Brohl AS, Eroglu Z, Tarhini AA, Khushalani NI, Hwu P, Mulé JJ, Sarnaik AA, Beatty MS, Pilon-Thomas S. Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma. Med (N Y). 2026 Aug.7(8):101231. Pubmedid: 42526429. Pmcid: PMC13425943.
• Simonovich JA, Clark RA, Kwiatkowski AJ, Fuchs MJ, Viso ME, Lu C, Macias SL, Pinto I, Shrestha AP, Ngo TB, Duarte S, He Y, Hu Q, Lu G, Hartman JB, Su G, Scali ST, Berceli SA, Sharma AK, Upchurch GR, Islam S, Wanchoo A, Hudalla GA, Robinson ST, Zarrinpar A, Avram D, Keselowsky BG. Circulating PEG-indoleamine 2,3-dioxygenase ameliorates diverse inflammatory diseases without toxicity or compromising immunocompetence. Proc Natl Acad Sci U S A. 2026 Jul.123(28):e2602536123. Pubmedid: 42418487. Pmcid: PMC13367878.
• Saha A, Whiting J, Mohty R, Flores K, Kim J, Nishihori T, Chavez J, Gaballa S, Khimani F, Liu H, Shah B, Dam M, Jaffer M, Mokhtari S, Ghalehsari N, Elmariah H, Bachmeier C, Guevara JA, Jim H, Mirza S, Segal BH, Hansen DK, Bejanyan N, Perna F, Faramand R, Jain M, Locke F, Lazaryan A. A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma. Bone Marrow Transplant. 2026 Jul. Pubmedid: 42469394.
• Rossetti RAM, Beatty MS, Cianne J, Ali JR, Harris K, Ramadan A, Grant M, Planes EM, Aurelio J, Karapetyan L, Creelan B, Pilon-Thomas S, Hwu P, Luca VC, Abate-Daga D. Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion. bioRxiv. 2026 Jul. Pubmedid: 42538952. Pmcid: PMC13419458.
• Jain N, Shi Y, May C, Mitra S, Bucher P, Dobrin A, Zhao Z, Hanina S, Rajasekhar VK, Yao Y, Mansilla-Soto J, Leibold J, Leslie CS, Sánchez-Rivera FJ, Feucht J, Sadelain M. Integrated Chronic In Vivo and In Vitro Screens Uncover NFIL3 as a Driver of T-cell Dysfunction. Cancer Discov. 2026 Jul.16(7):1456-1471. Pubmedid: 41747243.
• Navarre S, Ishibashi MN, Nair A, Reyes-Torres I, Belabed M, Halasz L, Park MD, Mattiuz R, Ounadjela M, Gunset G, Mansilla-Soto J, Feucht J, Cabriolu A, Le Berichel J, Birbrair A, Eyquem J, Brown BD, Merad M, Sadelain M, Ahmed J. Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases. Nat Cancer. 2026 Jul.7(7):1104-1120. Pubmedid: 42174275. Pmcid: PMC13400301.
• de Jong D, McGale JP, Robinson TJ, Liao MJ, Das JP, Major A, Capaccione KM, Ladbury C, Mansilla-Soto J, Ma H, Al Feghali KA, Goy AH, Lopci E, Reshef R, Schwartz LH, Houot R, Dercle L. CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment. J Nucl Med. 2026 Jul.67(7):1021-1031. Pubmedid: 42386374.
• Nguyen QT, Kim Y, Le THN, Garg S, Balkaran V, Bhathivi T, Chamizo A, Dukes CW, Ward K, Brohl AS, Karapetyan L, Khushalani NI, Eroglu Z, Tarhini AA, Mulé JJ, Markowitz J. iNOS is a key mediator of anti-PD-1 melanoma therapy response. Front Immunol. 2026 Jun.17:1837275. Pubmedid: 42440610. Pmcid: PMC13333588.
• Chakraborty P, Chatterjee S, Kassir MF, Wofford W, Choi S, Oleinik N, Saatci O, Darawshi O, Das S, Oberhoeltzer N, Gautam A, Mills S, DeMass R, Hedley Z, Liu Y, Parikh RY, Paul S, Seal S, Smith CD, Lilly MB, Gangaraju VK, Peterson Y, Mehrotra M, Hill E, Sahin O, Leitinger N, Rodriguez PC, Ogretmen B, Mehrotra S. Sphingosine kinase-2 inhibition promotes immunogenic differentiation of myeloid-derived suppressor cells through an Acetyl-CoA carboxylase-phosphatidylcholine axis. Nat Commun. 2026 Jun.17(1). Pubmedid: 42230631. Pmcid: PMC13392128.
• Guerriero JL, Merad M, Ginhoux F, Ostuni R, de Visser KE, Pittet MJ, Brandau S, Merghoub T, Egeblad M, Umansky V, van Vlerken-Ysla L, Marron TU, Coussens LM, Zarif JC, Ruffell B, Barry ST, Varner JA, Gabrilovich DI. Expert opinion on burning questions in cancer myeloid cell biology. J Immunother Cancer. 2026 Jun.14(6). Pubmedid: 42236113. Pmcid: PMC13239654.
• Onimus A, Celias D, Chang S, Davis J, Mandula J, Li J, Gardner A, Hänggi K, Osunmakinde O, Soliman H, Shaw TI, Rodriguez PC, Ruffell B. Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion. Cell Rep Med. 2026 May.7(5):102788. Pubmedid: 42097146. Pmcid: PMC13198304.
• Fisher J, Wu Y, Abate-Daga D, Barisa M, Lamb L. Harnessing the potential of γδ T cells through engineering and combination treatment for cancer therapies. Nat Commun. 2026 May.17(1). Pubmedid: 42173864. Pmcid: PMC13280018.
• Potez M, Jazayeri SB, Guske C, Miller J, Ali J, Carter M, Khambati F, Dhillon J, Sexton W, Zemp L, Manley B, Souza GR, Spiess PE, Beatty M, Pilon-Thomas S, Chahoud J. Feasibility and Functional Reactivity of Expanded Tumor-infiltrating Lymphocytes from Non-clear-cell Renal Cell Carcinoma. Eur Urol. 2026 May.89(5):469-471. Pubmedid: 40962596.
• Medina E, Mason C, Tran TH, Juliá EP, Ming Q, Taibi LM, Hwu P, Maute RL, Burg JS, Luca VC. Structural basis for sialoglycan recognition by the immune inhibitory receptor Siglec-10. Structure. 2026 May.34(5):768-777.e5. Pubmedid: 41747717.
• Medina CB, Sobierajska E, Gong M, McManus DT, Thapa M, Lee J, Im SJ, Toombs JE, Mitchell JM, Wang Y, Carlisle JW, Freeman GJ, Master VA, Ramalingam SS, Kissick HT, Li S, Brekken RA, Ahmed R. Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion. Nature. 2026 May.653(8115):879-887. Pubmedid: 41882354.
• Zhang Z, Ho YJ, Fang X, Kim M, Li M, Luan W, Hinterleitner C, Haubner S, Kogel F, Pratt EC, Ozcelik E, Reyes J, Jiang Q, Yang VW, Chen YJ, Wang T, Liu H, Hu H, Zhuang X, Park J, Paffenholz SV, Chen K, Chang Q, Kulick A, Zhang J, Chan E, Rosiek E, Fan N, Williams RA, Wang AC, Freeman S, Tian S, Gunset G, Garcia Angus A, Lecomte N, Yildirim SY, Ali E, Wu M, Miranda IC, Antonescu CR, Basturk O, Tarcan Z, Rekhtman N, Wilson C, Basar M, Sauter JL, Al-Ahmadie HA, Singer S, Iacobuzio-Donahue C, Rudin C, de Stanchina E, Ganesh K, Romesser PB, Weigelt B, Huh DD, Leibold J, Feucht J, Vázquez-García I, Bott MJ, Zamarin D, Shah SP, Lewis JS, Amor C, Pe'er D, Mansilla-Soto J, Filliol A, Sadelain M, Lowe SW. A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell. 2026 May.189(10):2898-2917.e42. Pubmedid: 41916312.
• Bryant JM, Sandoval M, Putney R, Trivedi P, Katende EN, Fink A, Naqvi SM, Kim Y, Yin V, Zhang J, Park JY, Serna A, Lam N, Pow-Sang J, Poch M, Li R, Manley BJ, Naghavi A, Torres-Roca J, Grass GD, Kim S, Latifi K, Hunt D, Johnstone P, Dhillon J, Rodriguez PC, Jain R, Fernandez DC, Yamoah K. Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. J Immunother Cancer. 2026 May.14(5). Pubmedid: 42082271. Pmcid: PMC13141221.
• Philbrook P, Dean MJ, Sanchez-Pino MD, Zheng LQ, Zabaleta J, Vázquez-Martínez JA, Chang D, Mandula JK, Shaw TI, Wyczechowska D, Garai J, Thylur Puttalingaiah R, Mansouri A, Huang W, Das S, Chang S, Conejo-Garcia JR, Rodriguez PC, Ochoa AC. Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer Immunol Res. 2026 Apr.14(4):640-657. Pubmedid: 41557755. Pmcid: PMC12990994.
• Perez DH, Antfolk D, Chang S, Bustos XE, Medina E, Ramadan AA, Gonzalez-Perez D, Abate-Daga D, Rodriguez PC, Luca VC. Engineering synthetic agonists for targeted activation of Notch signaling. Nat Chem Biol. 2026 Mar.22(3):392-401. Pubmedid: 40993428. Pmcid: PMC12953149.
• Potez M, Roman Souza G, Spiess PE, Pilon-Thomas S, Chahoud J. The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers. Nat Rev Urol. 2026 Mar.23(3):196-212. Pubmedid: 41006825.
• Prabhakaran S, Gatenbee CD, Robertson-Tessi M, Gahramanli Ozturk Z, Boyle TA, Gray JE, Antonia SJ, Gatenby RA, Beg AA, Anderson ARA. Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response. Cancer Res. 2026 Mar.86(5):1269-1285. Pubmedid: 41418101. Pmcid: PMC12871056.
• Karapetyan L, Kuriakose J, DiMaggio E, Ward K, Chau J, Otteni C, Kalos D, Ali J, Hall MS, Beatty M, Klinkova OV, Alomar ME, Gaskill EE, Gonzalez RM, Bailey H, Yu M, Tran N, Rodriguez-Alfonso L, Vieira E, Adams K, Jain M, Locke FL, Baldonado J, Perez MC, Mullinax J, Zager JS, Gonzalez R, Sondak VK, Markowitz J, Brohl AS, Eroglu Z, Tarhini AA, Khushalani NI, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients. Transplant Cell Ther. 2026 Mar.32(3):290.e1-290.e14. Pubmedid: 41421538.
• Du S, Nguyen KM, Ulezko Antonova A, Fachi JL, Rodrigues PF, Verdiani A, Molgora M, Smirnov I, Herz J, Mamuladze T, Ponce J, Swain A, Bugatti M, Gilfillan S, Cella M, Vermi W, Kipnis J, Colonna M, Brioschi S. Diversity and immune dynamics of choroid plexus macrophages are shaped by distinct developmental origins. Nat Neurosci. 2026 Mar.29(3):717-731. Pubmedid: 41566006.
• Du S, Nguyen KM, Ulezko Antonova A, Fachi JL, Rodrigues PF, Verdiani A, Molgora M, Smirnov I, Herz J, Mamuladze T, Ponce J, Swain A, Bugatti M, Gilfillan S, Cella M, Vermi W, Kipnis J, Colonna M, Brioschi S. Publisher Correction: Diversity and immune dynamics of choroid plexus macrophages are shaped by distinct developmental origins. Nat Neurosci. 2026 Mar.29(3):761. Pubmedid: 41644654.
• Nowak JA, Cho E, Davis MA, Zheng S, Bell L, Sha F, Magdalenski JS, Lui A, Napoli M, Falahat R, Mulé JJ, Flores ER, Farha OK, Teplensky MH. Strengthening Antisense Oligonucleotide-Mediated Anti-Tumor Immunity via Metal-Organic Framework Nanoparticles. Nano Lett. 2026 Mar.26(8):2861-2868. Pubmedid: 41712689.
• Garg SK, Snyder C, Ramamoorthi G, Kodumudi KN, Evans EE, Lok V, Bussler H, Nguyen JV, Yao J, Basu A, Gautam N, Vazquez Martinez JA, Chang DC, Aldrich AL, Wiener D, Rodriguez PC, Zauderer M, Koski GK, Czerniecki BJ. Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. Cell Rep. 2026 Mar.45(3):117050. Pubmedid: 41785084.
• Harman RC, Lozano I, Ramos K, Quilez-Alburquerque J, Gagnon J, Cheung S, Otero N, Johnson-Shoucair A, Kercher EM, Harris JE, Rizvi I, Pilon-Thomas S, Enderling H, Hasan T, Spring BQ. Cancer-selective photoimmunotherapy spares T cells and NK cells and promotes antitumor immunity in an allogeneic human 3D culture model. Photochem Photobiol. 2026 Mar. Pubmedid: 41889218.
• Oluwatola O, Bazargan S, Irrera P, Chang D, Thomas A, Blauvelt J, Beatty M, Hall M, Whelan CJ, Estrella V, Rejniak KA, Poch M, Fitzsimmons N, Beal R, Ibrahim-Hashim A, Pilon-Thomas S. Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer. Front Immunol. 2026 Mar.17:1706250. Pubmedid: 41909665. Pmcid: PMC13021593.
• Olumoyin KD, Aydin AM, Bazargan S, Bunch B, Chamseddine I, Karolak A, Beatty M, Pilon-Thomas S, Poch MA, Rejniak KA. PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers. bioRxiv. 2026 Mar. Pubmedid: 41959383. Pmcid: PMC13060882.
• Anderson HG, Bazargan S, Nusbaum DJ, Poch MA, Pilon-Thomas S, Rejniak KA. A virtual cohort framework with applications to adoptive cell therapy in bladder cancer. bioRxiv. 2026 Mar. Pubmedid: 41959223. Pmcid: PMC13060980.
• Calescibetta A, Dalton R, Fortenbery N, Ward G, Christiansen S, Chen X, Cheng P, Razabdouski T, Glode AJ, Tu N, Le Trinh T, Liu J, Wright KL, Wei S, Eksioglu EA. Correction: Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. PLoS One. 2026 Mar.21(4):e0348020. Pubmedid: 42018535. Pmcid: PMC13102199.
• Martinez-Planes E, Ramello MC, Fontela MG, Shokri MR, Darville L, Koomen J, Kim Y, Abate-Daga D. C-terminus CD28 phosphorylation (Y218) modulates IL-2 secretion and antitumor effect of CAR-T cells. bioRxiv. 2026 Feb. Pubmedid: 41659581. Pmcid: PMC12874040.
• Perez XB, Tordesillas L, Martinez-Planes E, Fontela MG, Rossetti RM, Izumi V, Fang B, Koomen J, Welsh E, Hwu P, Abate-Daga D. CAR Signaling Informs Mechanisms to EnhanceMetabolism and Function in γδ T Cells. Res Sq. 2026 Feb. Pubmedid: 41674831. Pmcid: PMC12889835.
• Fachi JL, de Oliveira S, Trsan T, Molgora M, Fernandes Rodrigues P, Gilfillan S, Ulezko Antonova A, Chang HW, Penati S, Cao S, Cella M, Colonna M. Divergent ILC3 responses to PDGF-D control mucosal immunity. Sci Immunol. 2026 Feb.11(116):eaea6848. Pubmedid: 41758927.
• Bryant JM, Shotbolt M, Stimphil E, Andre V, Zhang E, Estrella V, Husain K, Weygand J, Marchion D, Lopez AS, Abrahams D, Chen S, Abdel-Mottaleb M, Conlan S, Oraiqat I, Khatri V, Guevara JA, Pilon-Thomas S, Redler G, Latifi K, Raghunand N, Yamoah K, Hoffe S, Costello J, Frakes JM, Liang P, Gatenby RA, Malafa M, Khizroev S. Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models. Adv Sci (Weinh). 2026 Feb.13(9):e17228. Pubmedid: 41178530. Pmcid: PMC12904064.
• Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2026 Feb.32(3):501-515. Pubmedid: 41117857. Pmcid: PMC12667737.
• Ming Q, Luca VC. A little "BiTS" of LAG3 agonism, a big effect on T-cell autoimmunity. Immunol Cell Biol. 2026 Jan.104(1):4-6. Pubmedid: 41177146.
• Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Dec.43(12):2298-2310.e6. Pubmedid: 41072416. Pmcid: PMC12614569.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis. Int J Mol Sci. 2025 Dec.27(1). Pubmedid: 41515934. Pmcid: PMC12785608.
• Horta M, Augusto BM, Wright KL, Jacobsen P, Gonzalez B, Brandon TH, Vadaparampil ST, Simmons VN. 20 Years in the Making: Advancing Postdoctoral Training in Translational Behavioral Oncology. J Cancer Educ. 2025 Dec. Pubmedid: 41350962.
• Smalley TB, Nicolaci AA, Tran KC, Lokhandwala J, Obertopp N, Matlack JK, Miner RE, Teng MN, Pilon-Thomas S, Binning JM. Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer. Mol Ther. 2025 Nov.33(11):5415-5426. Pubmedid: 40873032. Pmcid: PMC12582245.
• Thatikonda S, Chaudhary R, Meshkovska Y, Biernacki M, Slebos RJC, Song X, Hall MS, Lilley K, Pilon-Thomas S, Guevara-Patino JA, Spiess PE, Chahoud J, Amelio AL, Wachter EA, Rodrigues D, Chung CH. PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis. Mol Cancer Ther. 2025 Nov.24(11):1733-1748. Pubmedid: 40552938. Pmcid: PMC12327362.
• Obertopp N, Bekker RA, Grass GD, Zelenka T, Thomas A, Potez M, Ali J, Blauvelt J, Hall AM, Hall MS, Chung CH, Enderling H, Pilon-Thomas S. Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes. Int J Radiat Oncol Biol Phys. 2025 Nov.123(4):1102-1115. Pubmedid: 40582598.
• Karapetyan L, Kuriakose J, Perez MC, Ali JR, Hall MS, Beatty MS, Otteni CD, Xu J, Kalos D, Moran-Segura C, Vieira E, Adams K, Rodriguez-Alfonso L, DiMaggio EC, Bailey H, Pinilla-Ibarz J, Locke FL, Mullinax JE, Chen PL, Song J, Messina JL, Johnson DB, Morgan DS, Eroglu Z, Khushalani NI, Sondak VK, Sarnaik AA, Tsai K, Mulé JJ, Pilon-Thomas S. Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. Front Immunol. 2025 Nov.16:1718443. Pubmedid: 41333460. Pmcid: PMC12665918.
• Obertopp N, Froid M, Pilon-Thomas S, Basanta D. Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling. bioRxiv. 2025 Nov. Pubmedid: 41332775. Pmcid: PMC12667981.
• Falahat R, Mulé JJ. Chemokine/cytokine-releasing biomaterials induce in situ tertiary lymphoid-like structures and enhance antitumor immunity. Proc Natl Acad Sci U S A. 2025 Nov.122(45):e2409560122. Pubmedid: 41183186. Pmcid: PMC12625823.
• Hänggi K, Ruffell B. Protocol for specific induction of apoptosis or necroptosis in established murine tumors. STAR Protoc. 2025 Nov.6(4):104185. Pubmedid: 41205180.
• Wang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P, Sukrithan V, Ratan A, McCarter M, Salhia B, Colman H, Naqash AR, Puzanov I, Arnold S, Marin-Acevedo JA, Ganesan S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini AA. Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nat Commun. 2025 Nov.16(1):9968. Pubmedid: 41233329. Pmcid: PMC12615696.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage-Tumor Interactions in the Glioblastoma Microenvironment. Cancers (Basel). 2025 Oct.17(19). Pubmedid: 41097797. Pmcid: PMC12523845.
• Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: 40845845.
• Hwang SM, Chang S, Rodriguez PC, Cubillos-Ruiz JR. Endoplasmic reticulum stress responses in anticancer immunity. Nat Rev Cancer. 2025 Sep.25(9):684-702. Pubmedid: 40555746. Pmcid: PMC12486299.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies. Cells. 2025 Sep.14(18). Pubmedid: 41002423. Pmcid: PMC12468907.